Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis - 25/01/24
, Maxime Pradier a, Barthelemy Lafondesmurs a, Pauline Thill a, Pierre Patoz b, Nicolas Blondiaux b, Donatienne Joulie c, Benjamin Hennart d, Olivier Robineau a, e, Eric Senneville a, eHighlights |
• | Dalbavancin has shown good results in patients with diabetes-related foot osteomyelitis. |
• | Dalbavancin tolerance profile is satisfactory. |
• | Dalbavancin is a good option in case of tolerance issues with previous treatments. |
• | Dalbavancin may ease discharge from hospital. |
Abstract |
Objectives |
We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation.
Patients and methods |
Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin.
Results |
Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission.
Conclusions |
In the study, dalbavancin was well-tolerated and showed microbiological and clinical efficacy.
Le texte complet de cet article est disponible en PDF.Keywords : Bone, Diabetes-related foot osteomyelitis, Dalbavancin, Treatment
Plan
Vol 54 - N° 1
Article 104835- février 2024 Retour au numéro
Article précédent
- The effects of switching from ceftriaxone to cefotaxime on the occurrence of third-generation cephalosporin-resistant Enterobacterales: A stepped-wedge cluster randomized trial
- Kevin Bouiller, Houssein Gbaguidi-Haore, Didier Hocquet, Thomas Crépin, Daniel Wendling, Sophie Borot, Catherine Chirouze, Xavier Bertrand
- Genomic and phenotypic diagnosis of bacterial meningitis in 25 health districts in Burkina Faso between January 2016 and December 2019
- Issa Tondé, Juliette Tranchot-Diallo, Dinanibè Kambiré, Absatou Ky-Ba, Mahamoudou Sanou, Idrissa Sanou, Rasmata Ouédraogo-Traoré
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?